Site notifications

Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

1073 result(s) found, displaying 151 to 175

  • AusPAR: Xembify

    Australian Public Assessment Report (AusPAR)
    AusPAR for Xembify (human normal immunoglobulin) for the treatment of primary immunodeficiency diseases.

  • AusPAR: Evusheld

    Australian Public Assessment Report (AusPAR)
    AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.

  • AusPAR: Kozenis

    Australian Public Assessment Report (AusPAR)
    AusPAR for Kozenis (tafenoquine) for prevention of relapse of Plasmodium vivax malaria in combination with chloroquine.

  • AusPAR: Nexviazyme

    Australian Public Assessment Report (AusPAR)
    AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.

  • AusPAR: Truseltiq

    Australian Public Assessment Report (AusPAR)
    AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.

  • AusPAR: Saphnelo

    Australian Public Assessment Report (AusPAR)
    AusPAR for SAPHNELO (anifrolumab) as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus.

  • AusPAR: Utrogestan 200

    Australian Public Assessment Report (AusPAR)
    AusPAR for Utrogestan 200 (progesterone) for the treatment of unexplained threatened miscarriage in women.

  • AusPAR: Apretude

    Australian Public Assessment Report (AusPAR)
    AusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.

  • AusPAR: Flucelvax Quad

    Australian Public Assessment Report (AusPAR)
    AusPAR for Flucelvax Quad (quadrivalent influenza vaccine) for the prevention of influenza.

  • AusPAR: Verzenio

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Verzenio (Abemaciclib) for the treatment of patients with HR+, HER2-, node-positive early breast cancer.

  • AusPAR: Xpovio

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Xpovio (selinexor) for treatment of relapsed or refractory multiple myeloma

  • AusPAR: Ponvory

    Australian Public Assessment Report (AusPAR)
    For the treatment of adult patients with relapsing forms of multiple sclerosis

  • AusPAR: Kimmtrak

    Australian Public Assessment Report (AusPAR)
    For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

  • AusPAR: Rybelsus

    Australian Public Assessment Report (AusPAR)
    Rybelsus (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

  • AusPar: Spikevax

    Australian Public Assessment Report (AusPAR)
    AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19

  • AusPAR: Yuflyma

    Australian Public Assessment Report (AusPAR)
    AusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.

  • AusPAR: Cosentyx

    Australian Public Assessment Report (AusPAR)
    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.

  • Isturisa

    Australian Public Assessment Report (AusPAR)
    AusPAR for Isturisa (osilodrostat as phosphate) for the treatment of endogenous Cushing’s syndrome in adults.

  • AusPAR: Dazalex SC

    Australian Public Assessment Report (AusPAR)
    AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis

  • AusPAR: Vaxneuvance

    Australian Public Assessment Report (AusPAR)
    AusPAR for Vaxneuvance (pneumococcal 15-valent conjugate vaccine (CRM197 protein), adsorbed) for the prevention of pneumococcal disease.

  • AusPAR: Sogroya

    Australian Public Assessment Report (AusPAR)
    AusPAR for SOGROYA (somapacitan) indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.

  • AusPAR: Tozinameran

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Comirnaty (tozinameran) for the prevention of COVID-19 in individuals 6 months of age and older.

  • AusPAR: Libtayo

    Australian Public Assessment Report (AusPAR)
    AusPAR for LIBTAYO (cemiplimab) for treatment of adult patients with locally advanced and metastatic basal cell carcinoma.

Help us improve this page